Merus

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merus and other ETFs, options, and stocks.

About MRUS

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. 

CEO
Sven Ante Lundberg
CEOSven Ante Lundberg
Employees
260
Employees260
Headquarters
Utrecht, Utrecht
HeadquartersUtrecht, Utrecht
Founded
2003
Founded2003
Employees
260
Employees260

MRUS Key Statistics

Market cap
7.28B
Market cap7.28B
Price-Earnings ratio
-18.01
Price-Earnings ratio-18.01
Dividend yield
Dividend yield
Average volume
1.08M
Average volume1.08M
High today
$96.28
High today$96.28
Low today
$95.80
Low today$95.80
Open price
$95.86
Open price$95.86
Volume
605.81K
Volume605.81K
52 Week high
$96.28
52 Week high$96.28
52 Week low
$33.19
52 Week low$33.19

Stock Snapshot

With a market cap of 7.28B, Merus(MRUS) trades at $95.98. The stock has a price-to-earnings ratio of -18.01.

During the trading session on 2025-11-14, Merus(MRUS) shares reached a daily high of $96.28 and a low of $95.80. At a current price of $95.98, the stock is +0.2% higher than the low and still -0.3% under the high.

Trading volume for Merus(MRUS) stock has reached 605.81K, versus its average volume of 1.08M.

Over the past 52 weeks, Merus(MRUS) stock has traded between a high of $96.28 and a low of $33.19.

Over the past 52 weeks, Merus(MRUS) stock has traded between a high of $96.28 and a low of $33.19.

MRUS News

Simply Wall St 13h
Did Rising Nine-Month Losses and Modest Revenue Growth Just Shift Merus' Investment Narrative?

Merus N.V. reported its third quarter 2025 earnings, showing revenue of US$12.15 million and a net loss of US$95.52 million, with the nine-month loss rising to...

Did Rising Nine-Month Losses and Modest Revenue Growth Just Shift Merus' Investment Narrative?
Nasdaq 1d
MRUS Crosses Above Average Analyst Target

In recent trading, shares of Merus NV (Symbol: MRUS) have crossed above the average analyst 12-month target price of $44.30, changing hands for $46.03/share. Wh...

MRUS Crosses Above Average Analyst Target
TipRanks 2d
Genmab Announces $2.5 Billion Note Offering for Merus Acquisition

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...

Analyst ratings

88%

of 17 ratings
Buy
11.8%
Hold
88.2%
Sell
0%

More MRUS News

TipRanks 2d
Merus N.V. Shareholders to Vote on Genmab Acquisition Offer

New activity is brewing for Merus ( (MRUS) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shar...

Simply Wall St 7d
Assessing Merus Valuation After Its Recent Surge in Share Price

Merus (MRUS) has caught the attention of many investors after its stock saw significant gains over the past month, as well as even more dramatic growth during t...

Assessing Merus Valuation After Its Recent Surge in Share Price

People also own

Based on the portfolios of people who own MRUS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.